Nucleoporin 107 is a prognostic biomarker in hepatocellular carcinoma associated with immune infiltration
- PMID: 36952458
- PMCID: PMC10225238
- DOI: 10.1002/cam4.5807
Nucleoporin 107 is a prognostic biomarker in hepatocellular carcinoma associated with immune infiltration
Abstract
Objective: To assess the diagnostic value and clinical significance of nucleoporin 107 (NUP107) in hepatocellular carcinoma (HCC), and explore the possible mechanisms.
Methods: The transcriptomic and clinical data of HCC patients were retrieved from The Cancer Genome Atlas (TCGA) and GEO databases. Tissue specimens were collected from HCC patients in the Guangxi area. According to the expression levels and prognostic characteristics of NUP107, ROC curves and nomogram models were constructed using the R package.
Results: NUP107 was highly expressed in 26 human cancers including HCC, and was associated with advanced HCC staging and worse prognosis. NUP107 showed satisfactory ability to predict the prognosis of HCC patients (AUC >0.8). Results of gene set enrichment analysis (GSEA) further showed that NUP107 was mainly associated with cell cycle-related pathways such as the cell cycle, DNA replication, G2M checkpoint, E2F target, and mitotic spindle. In addition, NUP107 was also associated with immune infiltration in HCC and showed significant positive correlation with immune checkpoints (PD-L1 and TIM-3).
Keywords: cell cycle; hepatocellular carcinoma; immune cells; immune checkpoints; nucleoporin 107 (NUP107).
© 2023 The Authors. Cancer Medicine published by John Wiley & Sons Ltd.
Conflict of interest statement
The authors have declared that there are no competing interests.
Figures










Similar articles
-
SART3, regulated by p53, is a biomarker for diagnosis, prognosis and immune infiltration in hepatocellular carcinoma.Aging (Albany NY). 2023 Aug 24;15(16):8408-8432. doi: 10.18632/aging.204978. Epub 2023 Aug 24. Aging (Albany NY). 2023. PMID: 37632835 Free PMC article.
-
[Analysis of correlation between high expression of nucleoporin 85 (NUP85) and immune cell infiltration in hepatocellular carcinoma].Xi Bao Yu Fen Zi Mian Yi Xue Za Zhi. 2024 Jun;40(6):508-519. Xi Bao Yu Fen Zi Mian Yi Xue Za Zhi. 2024. PMID: 38952090 Chinese.
-
Upregulated CANT1 is correlated with poor prognosis in hepatocellular carcinoma.BMC Cancer. 2023 Oct 19;23(1):1007. doi: 10.1186/s12885-023-11463-4. BMC Cancer. 2023. PMID: 37858061 Free PMC article.
-
High expression of PDZ-binding kinase is correlated with poor prognosis and immune infiltrates in hepatocellular carcinoma.World J Surg Oncol. 2022 Jan 22;20(1):22. doi: 10.1186/s12957-021-02479-w. World J Surg Oncol. 2022. PMID: 35065633 Free PMC article.
-
Analysis of Nucleoporin 107 Overexpression and Its Association with Prognosis and Immune Infiltration in Lung Adenocarcinoma by Bioinformatics Methods.Int J Gen Med. 2023 Nov 22;16:5449-5465. doi: 10.2147/IJGM.S441185. eCollection 2023. Int J Gen Med. 2023. PMID: 38021066 Free PMC article.
Cited by
-
Nuclear envelope and chromatin choreography direct cellular differentiation.Nucleus. 2025 Dec;16(1):2449520. doi: 10.1080/19491034.2024.2449520. Epub 2025 Feb 12. Nucleus. 2025. PMID: 39943681 Free PMC article. Review.
-
SART3, regulated by p53, is a biomarker for diagnosis, prognosis and immune infiltration in hepatocellular carcinoma.Aging (Albany NY). 2023 Aug 24;15(16):8408-8432. doi: 10.18632/aging.204978. Epub 2023 Aug 24. Aging (Albany NY). 2023. PMID: 37632835 Free PMC article.
-
Advances in the understanding of nuclear pore complexes in human diseases.J Cancer Res Clin Oncol. 2024 Jul 30;150(7):374. doi: 10.1007/s00432-024-05881-5. J Cancer Res Clin Oncol. 2024. PMID: 39080077 Free PMC article. Review.
-
Mutations in the NUP93, NUP107 and NUP160 genes cause steroid-resistant nephrotic syndrome in Chinese children.Ital J Pediatr. 2024 Apr 22;50(1):81. doi: 10.1186/s13052-024-01656-3. Ital J Pediatr. 2024. PMID: 38650033 Free PMC article.
-
Prognostic significance of LRPPRC and its association with immune infiltration in liver hepatocellular carcinoma.Am J Clin Exp Immunol. 2024 Jun 25;13(3):105-116. doi: 10.62347/XTLJ1335. eCollection 2024. Am J Clin Exp Immunol. 2024. PMID: 39022790 Free PMC article.
References
-
- Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2018;68(6):394‐424. - PubMed
-
- Sung H, Ferlay J, Siegel RL, et al. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2021;71(3):209‐249. - PubMed
-
- Fitzmaurice C, Allen C, Barber RM, et al. Global, regional, and national cancer incidence, mortality, years of life lost, years lived with disability, and disability‐adjusted life‐years for 32 cancer groups, 1990 to 2015: a systematic analysis for the global burden of disease study. JAMA Oncol. 2017;3(4):524‐548. - PMC - PubMed
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
Research Materials
Miscellaneous